Obstacles to Deprescribing Among French Patients Over 75 Years of Age Treated in the Geriatric Hospital Network (OUTMEDIC-FR)

H

Hôpital NOVO

Status

Completed

Conditions

Medication Abuse

Treatments

Other: self-questionnaire

Study type

Observational

Funder types

Other

Identifiers

NCT05327634
CHRD2921
2022-A00136-37 (Other Identifier)

Details and patient eligibility

About

The aim of this study is to highlight action guidelines to encourage acceptance of deprescribing in people over 75 years of age: training, therapeutic education, post-prescription follow-up, specific patient pathways, specific consultations or even the integration of an advanced practice nurse in this process.

Full description

For several years now, the proportion of senior citizens in our country has been rising steadily. There are now 6.4 million people over the age of 75 in France. It is therefore important to take into account the needs and specificities of this part of the population. One of its particularities is polypathology. Indeed, from the age of 70 onwards, 93% of elderly subjects have at least 2 diseases and 85% have at least 3. This polypathology will lead to a large number of different prescribers with an increased risk of having more than 5 molecules in their personal treatment. This is known as polypharmacy. In the elderly, polypharmacy is harmful. It increases the risk of adverse effects and drug interactions. In France, 20% of patients over 75 years old and 25% of those over 85 years old consult the emergency room because of adverse drug reactions. The literature shows that we can act on these adverse events by "deprescribing". De-prescribing is defined as intentionally stopping the prescription of an unnecessary or potentially dangerous drug for a patient. The expected benefit for the patient is to reduce the iatrogenic risks induced by treatments that would no longer be useful for him/her or that have a negative benefit/risk balance. To achieve this objective, the patient must understand this risk, understand the benefit he or she can derive from it and be an actor in this process. For carers, the expected benefit is greater involvement of the patient in the process, better adherence to the approach, which can be organised and carried out in a safer way.

Enrollment

120 patients

Sex

All

Ages

75+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients aged 75 years and over
  • Hospitalized in geriatric short-stay or geriatric rehabilitation units
  • Patients who did not object to participation in the study

Exclusion criteria

  • Patient refusal
  • Patients not able to understand and fill in the questionnaire: Cognitive disorders, Confusion, Unstable clinical state, Sensory disorders, not speaking French.
  • Patient under protective supervision (guardianship or curatorship)

Trial design

120 participants in 1 patient group

Deprescribing
Description:
Prospective study on patients aged 75 and over, hospitalised in geriatric short stay or geriatric rehabilitation units
Treatment:
Other: self-questionnaire

Trial contacts and locations

4

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems